Enanta Pharmaceuticals Files 2024 Annual Report

TL;DR

ENTA filed its 2024 10-K, all good on reporting. Check financials.

AI Summary

Enanta Pharmaceuticals, Inc. filed its annual report for the fiscal year ended September 30, 2024. The company is incorporated in Delaware and headquartered in Watertown, Massachusetts, with its common stock trading on NASDAQ under the symbol ENTA. The filing indicates that Enanta has met all reporting requirements for the preceding 12 months and the past 90 days, and has submitted all required Interactive Data Files electronically.

Why It Matters

This annual report provides investors with a comprehensive overview of Enanta Pharmaceuticals' financial health and operational status for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: low — The filing is a standard annual report and does not contain immediate red flags or significant negative disclosures.

Key Players & Entities

• Enanta Pharmaceuticals, Inc. (company) — Registrant
• September 30, 2024 (date) — Fiscal year end
• Delaware (jurisdiction) — State of incorporation
• Watertown, Massachusetts (location) — Principal executive offices
• 001-35839 (identifier) — Commission File Number
• 04-3205099 (identifier) — I.R.S. Employer Identification Number
• ENTA (ticker) — Trading Symbol
• NASDAQ (exchange) — Name of exchange

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ENTA NASDAQ Securities
• $17.46 — ice of the registrant's common stock of $17.46 per share was $ 347,379,533 . The numbe
• $248.2 million — ase. As of September 30, 2024, we had $248.2 million in cash, cash equivalents and short-ter

Filing Documents

• enta-20240930.htm (10-K) — 3241KB
• enta-ex10_26.htm (EX-10.26) — 29KB
• enta-ex10_27.htm (EX-10.27) — 38KB
• enta-ex10_28.htm (EX-10.28) — 38KB
• enta-ex10_29.htm (EX-10.29) — 62KB
• enta-ex10_30.htm (EX-10.30) — 46KB
• enta-ex10_31.htm (EX-10.31) — 27KB
• enta-ex19_1.htm (EX-19.1) — 125KB
• enta-ex21_1.htm (EX-21.1) — 8KB
• enta-ex23_1.htm (EX-23.1) — 4KB
• enta-ex31_1.htm (EX-31.1) — 12KB
• enta-ex31_2.htm (EX-31.2) — 12KB
• enta-ex32_1.htm (EX-32.1) — 7KB
• enta-ex97_1.htm (EX-97.1) — 16KB
• img52973840_0.jpg (GRAPHIC) — 2KB
• img216965693_0.jpg (GRAPHIC) — 664KB
• img216965693_1.jpg (GRAPHIC) — 1681KB
• img216965693_2.jpg (GRAPHIC) — 1255KB
• img216965693_3.jpg (GRAPHIC) — 1134KB
• img216965693_4.jpg (GRAPHIC) — 1381KB
• img216965693_5.jpg (GRAPHIC) — 756KB
• img216965693_6.jpg (GRAPHIC) — 1054KB
• img216965693_7.jpg (GRAPHIC) — 290KB
• img216965693_8.jpg (GRAPHIC) — 664KB
• 0000950170-24-131260.txt ( ) — 32923KB
• enta-20240930.xsd (EX-101.SCH) — 1476KB
• enta-20240930_htm.xml (XML) — 2308KB

Risk Factors

Risk Factors 32 1B. Unresolved Staff Comments 56 1C. Cybersecurity Risk Management and Strategy 56 2.

Properties

Properties 57 3.

Legal Proceedings

Legal Proceedings 57 4. Mine Safety Disclosures 57 PART II 5. Market for the Company's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 58 6. Reserved 59 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 60 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 70 8. Consolidated Financial Statements and Supplementary Data 70 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 71 9A.

Controls and Procedures

Controls and Procedures 71 9B. Other Information 71 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 71 PART III 10. Directors, Executive Officers and Corporate Governance 72 11.

Executive Compensation

Executive Compensation 72 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 72 13. Certain Relationships and Related Transactions, and Director Independence 73 14. Principal Accounting Fees and Services 73 PART IV 15. Exhibits and Financial Statement Schedules 74 16. Form 10-K Summary 76

Signatures

Signatures 77 SUMMARY OF PRINCIPAL RISK FACTORS This summary briefly states the principal risks and uncertainties facing our business that could affect our common stock, which are only a select portion of those risks. A more complete statement of those risks and uncertainties is set forth in the Section 1A "Risk Factors" of this report. This summary is qualified in its entirety by that more complete statement. You should carefully read the entire statement and "Risk Factors" when considering the risks and uncertainties as part of your evaluation of an investment in our common stock. We will require substantial additional funding to achieve our goals. If we do not generate sufficient funding from our existing collaboration and any future collaborations, we will need to obtain additional funding to support our operations. A failure to obtain funding when needed could force us to delay, limit, reduce or terminate some or all of our product development efforts. Our revenues for the next several years are substantially dependent upon AbbVie's success selling MAVYRET/MAVIRET, which includes our protease inhibitor, glecaprevir, for the treatment of HCV . AbbVie may continue to experience lower sales volume in future quarters, primarily due to a reduction in diagnoses and treatment rates of HCV. AbbVie's MAVYRET/MAVIRET regimen will have to continue to compete successfully against other products and therapies for HCV, including competition for exclusive arrangements with third-party payors and governmental entities as well as price competition, both in the U.S. and in other markets worldwide. Beginning after June 30, 2023, 54.5% of our reported revenues represent payments that go directly to OMERS following our April 2023 sale of that portion of our MAVYRET/MAVIRET royalties earned through June 30, 2032, subject to a cap on aggregate payments to OMERS equal to 1.42 times the purchase price. Any further changes in royalty revenue earned under our AbbVie agr

BUSINESS

BUSINESS Overview We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs with an emphasis on virology and immunology. Virology We discovered glecaprevir, the second of two antiviral protease inhibitors discovered and developed through our collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVie's leading brand of direct-acting antiviral, or DAA, combination treatment for HCV, which has been marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir) since 2017. Our active development programs in virology are focused on respiratory syncytial virus, or RSV, the most common cause of bronchiolitis and pneumonia and leading cause of U.S. hospitalization in young children and a significant cause of respiratory illness in older adults, with estimates suggesting that on average each year RSV leads to three million hospitalizations globally in children under 5 years old and 177,000 hospitalizations in the U.S. in adults over the age of 65. We also have development programs in virology for the following disease targets: SARS-CoV-2, the virus that causes COVID-19, with estimates suggesting that COVID-19 continues to have a disease burden greater than influenza, including persistent cases of infection often referred to as long COVID and hospitalization and death among the elderly and those with comorbidities, while new variants continue to emerge on a regular basis; and Hepatitis B virus, or HBV, the most prevalent chronic hepatitis, which is estimated by the World Health Organization to affect close to 300 million individuals worldwide. Immunology In immunology, we are designing and developing highly potent and selective, oral small molecule inhibitors for the treatment of inflammatory disease by targeting key mechanisms of immune response

View Full Filing

View this 10-K filing on SEC EDGAR